免疫系统
肿瘤微环境
癌症研究
血管生成
医学
细胞毒性T细胞
肿瘤缺氧
免疫疗法
免疫学
免疫检查点
生物
内科学
体外
生物化学
放射治疗
作者
Yu Shi,Yang Li,Baokang Wu,Chongli Zhong,Qi Lang,Zhiyun Liang,Yizhou Zhang,Chao Lv,Shushen Han,Yang Yu,Feng Xu,Yu Tian
标识
DOI:10.1016/j.intimp.2022.108968
摘要
Immune checkpoint inhibitors (ICIs) eliminate tumor cells by reactivating CD8 + T cells using the cytotoxic effects of the immune system. However, in this process, tumor angiogenic factors and abnormal formation of tumor blood vessels are not conducive to the treatment of ICIs. In the tumor microenvironment (TME), proangiogenic factors prevent dendritic cell maturation, reduce T cell infiltration, and recruit inhibitory immune cells such as regulatory T (Treg) cells. Abnormal tumor blood vessels also prevent immune cells and chemotherapy drugs from reaching the target effectively and lead to poor perfusion and severe hypoxia of the tumor. Treatment with antiangiogenic inhibitors can block the transmission of abnormal angiogenesis signals and promote the normalization of tumor vasculature. Therefore, the combination of antiangiogenic inhibitors and ICIs is used in clinical therapy. Combination therapy has been proven theoretically feasible in preclinical trials, and many clinical trials have been completed to confirm its safety and efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI